share_log

10-Q: Quarterly report

10-Q: Quarterly report

10-Q：季度报表
美股SEC公告 ·  2024/08/20 05:23

Moomoo AI 已提取核心信息

Firefly Neuroscience reported Q2 2024 revenue of $1.9 million, down 6% from $2.0 million in Q2 2023, primarily due to decreased professional services revenue. Gross profit declined 3.2% to $682,695, while gross margin improved slightly to 36.4%. The company posted an operating loss of $382,070 compared to operating income of $493,116 in the prior year quarter.The company significantly reduced operating expenses, with selling, general and administrative costs decreasing by $589,600 to $1.1 million, driven by lower acquisition costs, legal fees, and personnel expenses. As of June 30, 2024, Firefly had cash and equivalents of $244,137 and a working capital deficit of $746,040, raising substantial concerns about its ability to continue as a going concern.On August 12, 2024, the company completed its merger with Firefly Neuroscience 2023 and a concurrent $3.5 million private placement. The merged entity will focus on commercializing its FDA-cleared Brain Network Analytics platform for mental health diagnostics and treatment. Management expects continued negative cash flows as it invests in sales, marketing and platform development.
Firefly Neuroscience reported Q2 2024 revenue of $1.9 million, down 6% from $2.0 million in Q2 2023, primarily due to decreased professional services revenue. Gross profit declined 3.2% to $682,695, while gross margin improved slightly to 36.4%. The company posted an operating loss of $382,070 compared to operating income of $493,116 in the prior year quarter.The company significantly reduced operating expenses, with selling, general and administrative costs decreasing by $589,600 to $1.1 million, driven by lower acquisition costs, legal fees, and personnel expenses. As of June 30, 2024, Firefly had cash and equivalents of $244,137 and a working capital deficit of $746,040, raising substantial concerns about its ability to continue as a going concern.On August 12, 2024, the company completed its merger with Firefly Neuroscience 2023 and a concurrent $3.5 million private placement. The merged entity will focus on commercializing its FDA-cleared Brain Network Analytics platform for mental health diagnostics and treatment. Management expects continued negative cash flows as it invests in sales, marketing and platform development.
Firefly Neuroscience公布了2024年第二季度营业收入为190万美元，比2023年第二季度的200万美元下降了6%，主要由于专业服务收入减少。毛利润下降了3.2%，为682,695美元，而毛利率略微改善至36.4%。该公司报告的营业亏损为382,070美元，而去年同期为营业收入493,116美元。该公司显著降低了营业费用，销售、一般和行政费用减少了589,600美元，降至110万美元，主要由于降低了收购成本、法律费用和人员开支。截至2024年6月30日，Firefly的现金及现金等价物为244,137美元，营运资金赤字为746,040美元，这引发了对其是否能持续经营的重大担忧...展开全部
Firefly Neuroscience公布了2024年第二季度营业收入为190万美元，比2023年第二季度的200万美元下降了6%，主要由于专业服务收入减少。毛利润下降了3.2%，为682,695美元，而毛利率略微改善至36.4%。该公司报告的营业亏损为382,070美元，而去年同期为营业收入493,116美元。该公司显著降低了营业费用，销售、一般和行政费用减少了589,600美元，降至110万美元，主要由于降低了收购成本、法律费用和人员开支。截至2024年6月30日，Firefly的现金及现金等价物为244,137美元，营运资金赤字为746,040美元，这引发了对其是否能持续经营的重大担忧。在2024年8月12日，公司完成了与Firefly Neuroscience 2023的合并以及同时进行的350万美元定向增发。合并后的实体将专注于商业化其获得FDA批准的脑网络分析平台，用于心理健康诊断和治疗。管理层预计在投资于销售、市场营销和平台开发时将出现持续的负现金流。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Femto Technologies
    FMTO
    -- 3.680
    Blaize Holdings
    BZAI
    -- 5.150
    三易科技
    MASK
    -- 2.770
    Intelligent Protection Managem
    IPM
    -- 2.150
    Alpha Modus Holdings
    AMOD
    -- 2.650
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。